



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/748,094	12/31/2003	Gautam Vinod Daftary	12879/2	6940
7590	07/23/2007		EXAMINER	
Teresa A. Lavenue Kenyon & Kenyon Suite 700 1500 K. Street, N.W. Washington, DC 20005			KISHORE, GOLLAMUDI S	
			ART UNIT	PAPER NUMBER
			1615	
			MAIL DATE	DELIVERY MODE
			07/23/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/748,094	DAFTARY ET AL.
	Examiner Gollamudi S. Kishore, Ph.D	Art Unit 1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 04 May 2007.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-8,10-22,61 and 62 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-8,10-22,61 and 62 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 11-10-04 ; 3-12-04
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) Notice of Informal Patent Application
- 6) Other: _____

DETAILED ACTION

1. Applicant's election without traverse of Group I in the reply filed on 5-4-07 is acknowledged.

Claims included in the prosecution are 1-8, 10-22 and 61-62.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claim 62 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The dependency of claim 62 is unclear.

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

5. Claims 1-8, 10-22 and 61 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kirpotin (6,110,491).

Kirpotin discloses a method of preparation of liposomes by forming a lipid film and hydrating it with a buffer containing ammonium sulfate (Example 7). Kirpotin also teaches that if necessary, to achieve an osmolarity of 377 mmol/kg, sucrose could be added to the medium (Example 8). The liposomes contain hydrogenated egg phospholipid and cholesterol. Doxorubicin is loaded into the preformed liposomes (Example 7). What is lacking in Kirpotin is the teaching of the amount of aqueous medium added to per mol phospholipid. However, since the final product in Kirpotin is a liposome just as in instant case, in the absence of showing unexpected results, it is deemed obvious to one of ordinary skill in the art to vary the amounts of the hydrating medium to obtain the best possible results.

6. Claims 1-8, 10-22 and 61-62 are rejected under 35 U.S.C. 103(a) as being unpatentable over Forssen (5,714,163) in combination with Janoff (4,880,635).

Forssen discloses a method of preparation of liposomes wherein the lipid film is hydrated with ammonium sulfate. The liposomes contain DSPC and cholesterol and vincristine. Vincristine is added to the preformed liposomes (Example 1). Although Forssen teaches the use of 300 mM sucrose, he does not teach the use of hydration buffer containing both ammonium sulfate and sucrose.

Janoff teaches that sugars such as sucrose when present both inside and outside would enable the liposomes to retain Adriamycin during dehydration and rehydration (col. 21, line 23 through col. 21, line 27).

To include sucrose in the hydration medium of Forssen would have been obvious to one of ordinary skill in the art since such a procedure would enable the presence of

Art Unit: 1615

sucrose within the liposomes as well as outside and since Janoff teaches that the liposomes retain the active agent during dehydration and rehydration procedures. Although Forssen does not specifically teach the amount of aqueous medium added per mol phospholipids, since the final product in Forssen is a liposome just as in instant case, in the absence of showing unexpected results, it is deemed obvious to one of ordinary skill in the art to vary the amounts of the hydrating medium to obtain the best possible results.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gollamudi S. Kishore, Ph.D whose telephone number is (571) 272-0598. The examiner can normally be reached on 6:30 AM- 4 PM, alternate Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Woodward Michael can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Gollamudi S Kishore, Ph.D
Primary Examiner
Art Unit 1615

GSK